Boston Taiwanese Biotechnology Association (BTBA) is a non-profit organization started in 2012 by a group of Taiwanese graduate students, postdocs and young professionals in the greater Boston area. Our goals are to foster individual career development, to enhance scientific collaborations, to facilitate interactions and to strengthen networking among academic and industrial bioscience communities in Taiwan and US.
Mar 15, 2025
在當前的科技與生技領域,計算基因組學正逐漸成為一項重要的研究方向。然而,若是你,什麼原因會促使你選擇從一位炙手可熱的電機工程師,轉向生命科學的探索?這樣的轉變對許多人來說並不常見,但對陳乃群博士 ...More info
Mar 01, 2025
人工智慧(AI)如何改變藥物開發?藥物開發從臨床前研究到臨床試驗,通常需要超過十年時間和數十億美元的投資,卻仍有高達九成的藥物在臨床試驗中失敗。這些挑戰,現在 AI 正在各種方面掀起革命。在這系 ...More info
Feb 15, 2025
腹腔壓力異常 (Intra-abdominal Hypertension, IAH) 是重症病房 (ICU) 患者常見但監測率極低的問題。估計超過 60% 的 ICU 病人可能有腹腔壓力過高的問 ...More info
By 文:林書弘.圖:陳政儀.編輯:劉駿 on Nov, 2024
在《生技來一刻》第四季第十二集的訪談中,主持人奕芸邀請到了黃正球博士(Joe),現任Eli Lilly神經科學部門的高階主管,來分享他在神經藥物研發領域的經驗與見解。 黃博士擁有豐富的學術背景與業界經歷,從臺灣大學動物系畢業後一路深造,最終在美國加入生技與製藥產業,專注於神經疾病的藥物開發。這次訪談深入探討了神經科學領域的現況與未來趨勢,對生技業界尤其是從事神經科學的聽眾提供了許多寶貴的洞見。 ...Read more
By 文:林書弘.圖:陳政儀.編輯:劉駿 on Apr, 2024
在現今的生技產業中,投資組合管理與數據分析技術的重要性日益增加。尤其在藥物開發這一高風險領域,有效的策略和先進的技術可以顯著提升研發的成功率及市場競爭力。透過近期與羅盈智醫師(Paul)的對話,我們得以深入了解這些策略如何在實際應用中發揮作用。 Paul目前在美國波士頓的 Novartis 藥廠擔任 Portfolio Data Science 部門的副總監,同時也是波士頓台灣醫師協會的會長。他的職業生涯跨越了醫療、人工智慧和商業策略,這使他對於藥廠如何進行投資組合管理有著獨到的見解。 ...Read more
By Yi-Shan Chen on Mar, 2019
As a scientist in Biotech/Pharma, Business Development to me is a function that usually doesn’t have a lot of interaction with researchers unless they need data from you but the decisions they make influence researchers the most. ...Read more
By Yi-ying Chou on Nov, 2018
I always thought that doing biological experiments, like sitting long hours in front of tissue culture hood, can be physically challenging. When I chat with Ryan, I realized that medicinal chemists also have heavy workload on the bench side. In pharmaceutical company, chemists are not allowed to be ...Read more